Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
79.8M
-
Number of holders
-
159
-
Total 13F shares, excl. options
-
31.7M
-
Shares change
-
+2.81M
-
Total reported value, excl. options
-
$296M
-
Value change
-
+$18.2M
-
Put/Call ratio
-
0.45
-
Number of buys
-
98
-
Number of sells
-
-61
-
Price
-
$9.33
Significant Holders of Niagen Bioscience, Inc. - Common Stock (NAGE) as of Q3 2025
192 filings reported holding NAGE - Niagen Bioscience, Inc. - Common Stock as of Q3 2025.
Niagen Bioscience, Inc. - Common Stock (NAGE) has 159 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.7M shares
of 79.8M outstanding shares and own 39.78% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (4.02M shares), BlackRock, Inc. (3.98M shares), Tieton Capital Management, LLC (1.65M shares), ARROWSTREET CAPITAL, LIMITED PARTNERSHIP (1.44M shares), GEODE CAPITAL MANAGEMENT, LLC (1.3M shares), UBS Group AG (1.2M shares), STATE STREET CORP (1.09M shares), Qube Research & Technologies Ltd (876K shares), Nuveen, LLC (791K shares), and MILLENNIUM MANAGEMENT LLC (774K shares).
This table shows the top 159 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.